Pancreatic Adenocarcinoma
Conditions
Brief summary
This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with advanced unresectable pancreatic carcinoma. Clinical data from patients diagnosed with pancreatic adenocarcinoma will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of Medical Oncology of the University Department of Medicine, Queen Mary Hospital, Hong Kong.
Interventions
DRUGCapecitabine
1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
DRUGOxaliplatin
70 mg/m2 IV on day 1 of a 2-week cycle
DRUGIrinotecan
130 mg/m2 IV on day 1 of a 2-week cycle
Sponsors
The University of Hong Kong
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults ≥ 18 years of age, male or female. * Histopathologically or cytologically confirmed adenocarcinoma of the pancreas. * ECOG performance status 0 to 2. * Adequate bone marrow reserve. * Absolute neutrophil count \> 1x10\^9/L. * Total bilirubin \<3 times the upper limit of the normal range. * Life expectancy ≥ 12 weeks. * Signed written informed consent form.
Exclusion criteria
* Prior malignant disease other than pancreatic cancer. * Patients suitable for surgical or locoregional therapies. * Patients who have prior anticancer therapy for pancreatic cancer. * Patients unable to swallow oral medications. * Any evidence of brain metastasis (unless the patient is \>6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry). * Active clinically serious infections (\> grade 2 NCI / CTC Adverse Event version 3.0). * History of allergy to platinum compounds. * Patients who have chronic inflammatory bowel disease and/or bowel obstruction. * Patients who have severe bone marrow failure. * Patients undergoing renal dialysis. * History of HIV infection. * Seizure disorder requiring medication (such as steroids or anti-epileptics). * Women who are pregnant or breast-feeding, or women of child-bearing potential who are unable or unwilling to practice a highly effective means of contraception. * Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of study results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in extent of disease | Change from baseline in size approximately every 4 cycles | Objective response rate |
Secondary
| Measure | Time frame |
|---|---|
| CA19.9 reduction | Change from baseline every 2 cycles |
| Progression-free survival | From date of start until the date of first documented progression or death from disease-related causes or last follow-up, whichever came first, assessed up to 18 months |
| Overall survival | From date of start until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months |
Countries
Hong Kong
Outcome results
None listed